ItzBio SB – 65 mg

Product Overview

  • With the advent of multiple variants of fungus & constant development of microbial resistance against various antifungal medications, effective oral antifungal is the need of the hour.
  • Recent studies with oral Itraconazole have shown an effective result against various dermatophytosis.
  • So, we are introducing a novel formulation of SUBA (Superior bioavailable) itraconazole that utilizes a unique spray-drying/double drying technology producing microencapsulated form of nanoparticles of itraconazole dispersed in a polymer matrix instead of conventional crystalline form to enhance the solubility & bioavailability of the poorly soluble oral medication


Chronic recalcitrant endemic & systemic dermatophytosis (yeast & moulds)

  • Blastomycosis
  • Aspergillosis
  • Histoplasmosis
  • Candidiasis
  • Onychomycosis

Why choose SUBA Itraconazole?

Clinical studies with SUBA have also shown-

  • Lesser patient variability than conventional itraconazole.
  • 100% patients were above the therapeutic threshold.
  • Itraconazole SB was safe & well-tolerated.
  • Up to 90% bioavailable with improved overall absorption & consistent plasma levels.
  • Therapeutic levels are achieved & maintained.
  • Delivery of consistent blood levels of itraconazole for lower patient variability.
  • As the drug is released in the small intestine so absorption of it is not reduced.
  • It comes in dosage of 65 mg & 130 mg.
  • This technology delivers nearly double the bioavailability of conventional 100 mg.
  • Itraconazole capsules in a smaller 65 mg dose.

Conventional Vs SUBA Itraconazole

Conventional Itraconazole SUBA Itraconazole
No advanced delivery technology Novel SUper BioaAailable delivery technology
Poor bioavailability ~2x bioavailability
Affected by food Maintained uniform therapeutic levels in fed & fasted state
Affected by co-administration of PPIs (antacids) Absorption not affected by co-administration of PPIs
Low pH required (stomach) for release & absorption of drug Non-reliance on acidic pH of stomach due to SUBA technology


  • Patients ≥ 18 years.
  • Immunocompromised & non-immunocompromised patients.
  • Should be non-pregnant and not breastfeeding (and not planning to become pregnant).
  • Significant liver dysfunction.
  • Documented intolerance, allergy or hypersensitivity to itraconazole.
  • Known history or presence of congestive cardiac failure.


  • This medicine works by killing the fungus or yeast and preventing its growth.
  • Itraconazole capsule is used to treat fungal infections, such as aspergillosis (fungal infection in the lungs), blastomycosis, or histoplasmosis.


Directions for Use

  • As recommended by the physician


  • Wherever conventional 100 mg twice daily dose is given 65 mg would do
  • SUBA 130 mg maybe given as single dose wherever conventional 200 mg is prescribed

Common adverse reactions may be

  • Nausea, rash, vomiting, headache, diarrhoea, fatigue, abdominal pain etc. can be seen which has an incidence of >1%.
  • Hence patient’s reaction towards the medication must be observed as a precautionary measure.

Contraindications can be-

  • Co-administration with certain drugs which can interact with itraconazole/patients having hypersensitivity towards itraconazole